Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.58 |
| ▸ | MAOA | P21397 | 16/20 | 0.58 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758928 | 1.00 | MAOB (0.58) | MAOBMAOAPRKCIHSD17B1CES1 | |
| SCHEMBL17261615 | 0.97 | MAOB (0.58) | MAOBMAOAPRKCICES1 | |
| SCHEMBL30966007 | 0.91 | MAOB (0.53) | MAOBMAOAPRKCIHSD17B1 | |
| SCHEMBL1239457 | 0.90 | MAOB (0.60) | MAOBMAOAHSD17B1CES1 | |
| SCHEMBL30837166 | 0.88 | HSD17B1 (0.60) | MAOBMAOAPRKCIHSD17B1 | |
| SCHEMBL26706343 | 0.87 | MAOA (0.54) | MAOBMAOAPRKCICES1 | |
| SCHEMBL20211855 | 0.84 | MAOB (0.55) | MAOBMAOAPRKCIHSD17B1 | |
| SCHEMBL29772190 | 0.84 | MAOB (0.55) | MAOBMAOAPRKCIHSD17B1 | |
| SCHEMBL23519222 | 0.84 | MAOB (0.52) | MAOBMAOAPRKCIHSD17B1 | |
| SCHEMBL315565 | 0.81 | MAOB (0.55) | MAOBMAOAPRKCIHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| EP-4265613-A1 | BENZENE RING COMPOUND AND USE THEREOF | Nanjing Shijiang Medicine Technology Co., Ltd (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-8952151-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952151-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952151-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8889906-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2014100818-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100818-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | MAOB 473/4885MAOA 430/4885PRKCI 2341/4885 |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | MAOB 3338/4885MAOA 3468/4885PRKCI 544/4885 |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, RIF1, TTR | MAOB 1590/4885MAOA 1589/4885PRKCI 3660/4885 |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT8 | MAOB 3204/4885MAOA 3418/4885PRKCI 471/4885 |
| US-11639333-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | MAOB 473/4885MAOA 430/4885PRKCI 2341/4885 |
| US-11725001-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | MAOB 3338/4885MAOA 3468/4885PRKCI 544/4885 |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | MAOB 473/4885MAOA 430/4885PRKCI 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.